Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To manufacture ICT-121, cancer stem cell vaccine for upcoming clinical trial
Subscribe to our email newsletter
ImmunoCellular (IMUC) has signed an agreement with Formatech for the manufacture of IMUC’s cancer stem cell vaccine, ICT-121, for an upcoming clinical trial. ICT-121 is a product candidate that targets cancer stem cells and may have applicability to multiple types of cancer.
The company said that the phase-I clinical trial of ICT-121 will target glioblastoma, and is expected to begin early next year. The company’ yet to get FDA clearance for ICT-121.
The agreement calls for Formatech to prepare the vials of cancer vaccine for the clinical trial, under a GMP (Good Manufacturing Practices) environment.
Manish Singh, President and CEO of IMUC, said: We are particularly excited by ICT-121 given that it targets cancer stem cells, an approach which we believe could have a persistent and lasting effect in fighting a patient’s cancer.
ICT-121 has shown its ability in preclinical studies to target and destroy cancer stem cells present in brain tumors, so we are excited to initiate this trial in the coming months with the ultimate goal of being able to someday offer to patients a safer and more effective treatment alternative than the current standard of care, he added.